News Archive

Our latest announcements or presentations are available by selecting the desired News Type.

Announcements can be further filtered by topic using the News Topic check boxes.

 

The full text of all announcements are available for download in the form of PDF files.  For convenience, the text of some announcements have been partially or fully rendered as web pages.  Should any inconsistencies exist, the PDF version shall prevail.

News Type
Presentations
RNS Announcements
News Topics
Commercial Platform
Group
Innovation Platform
Regulatory Notice
1
2345678910111213
found Documents: 630
Live virtual investor conference. Time: 01:30 pm GMT (09:30 pm HKT/08:30 am EST) >> Click here for the webcast  
Read More
Presentation Date: Wednesday Nov 20, 2019 Presentation Time: 1:30 pm (China Time) Location: Jing An Shangri-La, Shanghai
Read More
London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the following conferences: Deutsche Bank Depositary Receipts Virt
Read More
London: Monday, November 11, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that its New Drug Application (“NDA”) for surufatinib for the treatment of patients with advanced non-pancreatic neuroendocrine
Read More
Dr. Alec W. Stranahan +1 646 743 2109 alec.stranahan@bofa.com
Read More
Lotte New York Palace, New York >>  Send us your inquiry
Read More
Presentation Date: Monday Nov 25, 2019 Presentation Time: 11:30 am (HKT) Location: Conrad Hotel, Hong Kong  
Read More
Waldorf Hilton, London >>  Send us your inquiry
Read More
London: Thursday, October 17, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today highlighted the publication of results from the Phase II VIKTORY (targeted agent eValuation In gastric cancer basKeT KORea studY) trial in Ca
Read More
London: Thursday, October 10, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announces that on October 9, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Me
Read More
Suzhou, China and London, UK, Thursday, October 10, 2019 — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) and Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration ag
Read More
London: Friday, October 4, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with relapsed or refr
Read More
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION   London: Monday, September 30, 2019: Hutchison Chin
Read More
London: Monday, September 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at September 30, 2019, the issued share capital of Chi-Med consisted of 666,786,450 ordinary shares of US$0.10 e
Read More
Press release released:  September 29, 2019 (Sun)  >> See press release here Presentation webcast & call:  September 30, 2019 (Mon) 2pm CEST (1pm BST/8am EDT/8pm HKT) >> Click here for the webcast replay
Read More
Title:   Efficacy and Safety of Surufatinib in Patients with Well-Differentiated Advanced Extrapancreatic Neuroendocrine Tumors: Results from the Randomized Phase III Study (SANET-ep) Presenting Author: Jianming Xu, Head of th
Read More
Press Release – Surufatinib achieved primary endpoint, reducing the risk of progression or death by 67% in patients with non-pancreatic neuroendocrine tumors (“NET”) in the Phase III SANET-ep study – – Preparations underway for the potent
Read More
– Late-Breaking Abstract of the positive SANET-ep Phase III trial of surufatinib in patients with non-pancreatic neuroendocrine tumors (“NET”) to be presented – – Conference call and webcast with lead trial investigators to be held on Mond
Read More
Presentation Title : Association Between Hand-Foot Skin Reaction and Survival Benefit of Fruquintinib in FRESCO Trial Presenting Author: Yuxian Bai, Harbin Medical University Cancer Hospital Other Authors: Jin Li, Shukui Qin, Yanho
Read More
Presentation Title : Subgroup Analysis of Patients With Metastatic Colorectal Cancer Treated With Fruquintinib in the FRESCO Trial Who Had Liver Metastasis Presenting Author: Shukui Qin, Nanjing Chinese Medicine University Affiliated Bay
Read More
London: Wednesday, September 18, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) shares additional analyses from three completed and ongoing clinical studies of fruquintinib and savolitinib at the 22nd Annual Meeting of the C
Read More
MA14.05 - A Randomized Phase III Trial of Fruquintinib Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (FALUCA)   Venue: IASLC 2019 World Conference on Lung Cancer in Barcelona, Spain Session:MA14 - The Adequate MTarget
Read More
Location: New York, NY, United States Time: 09:55 AM EDT >> Click here for the webcast  
Read More
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will participate in a fireside chat at Morgan Stanley 17th Annual Global Healthcare C
Read More
London: Tuesday, September 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated an international Phase I/Ib study of HMPL-689, its novel, highly selective and potent small molecule phosphoinositide-3 kinase delta
Read More
London: Friday, August 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) hereby notifies the market that as at August 30, 2019, the issued share capital of Chi-Med consisted of 666,777,450 ordinary shares of US$0.10 each, w
Read More
London: Friday, August 23, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a Phase I study of HMPL-523, its novel spleen tyrosine kinase (“Syk”) inhibitor, in patients with immune thrombocytopenia (“ITP”
Read More
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
Contents Corporate Information Contents 1 Financial Highlights 2 Operating Highlights 3 Chairman’s Statement6 6 Financial Review 7 Operations Review     Innovation Platform     Comme
Read More
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
Announcement released: 7am BST (2pm HKT/2am EDT)  >> See announcement here Presentation webcast & call: 9am BST (4pm HKT/4am EDT) >> Click here for the webcast US conference call: 9am EDT (2pm BST/9pm HKT)
Read More
London: Tuesday, July 30, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its unaudited financial results for the six months ended June 30, 2019 and provides updates on key clinical programs.  Major highlight
Read More
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hutch
Read More
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: Hut
Read More
London: Wednesday, July 3, 2019: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will be announcing its interim results for the six months ended June 30, 2019 on Tuesday, July 30, 2019 at 7:00 am British Summer Time (BST) (2:00 pm
Read More
London: Friday, June 28, 2019: Hutchison China MediTech Limited (“Chi-Med” or the “Company”) (AIM/Nasdaq: HCM) announces the following blocklisting six monthly return:   1. Name of applicant: Hutchison China MediTech Limite
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 28, 2019: Hutchison China MediTech Limited (“
Read More
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION London: June 27, 2019: Hutchison China MediTech Limited (“
Read More